Dynamic Light Scattering Analysis for the Determination of the Particle Size of Iron-Carbohydrate Complexes

Burgert, Michael; Marques, Cintia; Borchard, Gerrit; Philipp, Erik; Wilhelm, Maria; Alston, Amy Barton; Digigow, Reinaldo

doi:10.3791/63820

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[30] The results of dynamic light scattering (DLS) measurements showed that the hydrodynamic diameter was about 209.2 ± 8.7 nm and the zeta potential was −7.20 ± 0.78 mV (Figure 1b). [31] The stability of the Bev-IR820@Fe III TA nanoparticle was evaluated Scheme 1. a) The formation of Bev-IR820@Fe III TA. b) Schematic illustration of combined anti-angiogenic/photothermal/ferroptosis therapy for esophageal cancer.…”

Section: Characterization and Cellular Uptake Of Bev-ir820@fe III Tamentioning

confidence: 99%

Self‐Assembled Acid‐Responsive Nanosystem for Synergistic Anti‐Angiogenic/Photothermal/Ferroptosis Therapy against Esophageal Cancer

Li,

et al. 2023

Adv Healthcare Materials

View full text Add to dashboard Cite

Esophageal cancer (EC) treatment via anti‐angiogenic therapy faces challenges due to non‐cytotoxicity and non‐specific biodistribution of the anti‐angiogenic agents. Hence, the quest for a synergistic treatment modality and a targeted delivery approach to effectively address EC has become imperative. In this study, an acid‐responsive release nanosystem (Bev‐IR820@FeIIITA) that involves the conjugation of bevacizumab, an anti‐angiogenic monoclonal antibody, with TA and Fe3+ to form a metal‐phenolic network, followed by loading with the near‐infrared photothermal agent (IR820) to achieve combinational therapy, is designed. The construction of Bev‐IR820@FeIIITA can be realized through a facile self‐assembly process. The Bev‐IR820@FeIIITA exhibits tumor‐targeting capabilities and synergistic therapeutic effects, encompassing anti‐angiogenic therapy, photothermal therapy (PTT), and ferroptosis therapy (FT). Bev‐IR820@FeIIITA exhibits remarkable proficiency in delivering drugs to EC tissue through its pH‐responsive release properties. Consequently, bevacizumab exerts its therapeutic effects by obstructing tumor angiogenesis, thereby impeding tumor growth. Meanwhile, PTT facilitates localized thermal ablation at the tumor site, directly eradicating EC cells. FT synergistically collaborates with PTT, giving rise to the formation of a reactive oxygen species (ROS) storm, subsequently culminating in the demise of EC cells. In summary, this amalgamated treatment modality carries substantial promise for synergistically impeding EC progression and showcases auspicious prospects for future EC treatment.

show abstract

Section: Characterization and Cellular Uptake Of Bev-ir820@fe III Tamentioning

confidence: 99%

Self‐Assembled Acid‐Responsive Nanosystem for Synergistic Anti‐Angiogenic/Photothermal/Ferroptosis Therapy against Esophageal Cancer

Li,

et al. 2023

Adv Healthcare Materials

View full text Add to dashboard Cite

show abstract

Dynamic Light Scattering Analysis for the Determination of the Particle Size of Iron-Carbohydrate Complexes

Cited by 1 publication

References 0 publications

Self‐Assembled Acid‐Responsive Nanosystem for Synergistic Anti‐Angiogenic/Photothermal/Ferroptosis Therapy against Esophageal Cancer

Self‐Assembled Acid‐Responsive Nanosystem for Synergistic Anti‐Angiogenic/Photothermal/Ferroptosis Therapy against Esophageal Cancer

Contact Info

Product

Resources

About